ChiCTR2500096736 版本V1.0 版本创建时间2025/02/05 16:10:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500096736 

最近更新日期:

Date of Last Refreshed on:

2025-02-05 16:09:21 

注册时间:

Date of Registration:

2025-02-05 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

自动脚踝运动预防神经重症昏迷患者下肢深静脉血栓形成的概念验证研究

Public title:

Proof-of-concept study of automatic ankle exercise to prevent deep venous thrombosis of lower limbs in patients with severe neurological coma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

自动脚踝运动预防神经重症昏迷患者下肢深静脉血栓形成的概念验证研究

Scientific title:

Proof-of-concept study of automatic ankle exercise to prevent deep venous thrombosis of lower limbs in patients with severe neurological coma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王娜 

研究负责人:

王娜 

Applicant:

Na Wang 

Study leader:

Na Wang 

申请注册联系人电话:

Applicant telephone:

+86 13811391616

研究负责人电话:

Study leader's telephone:

+86 13811391616

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangna163_com@126.com

研究负责人电子邮件:

Study leader's E-mail:

wangna163_com@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号 首都医科大学宣武医院

研究负责人通讯地址:

北京市西城区长椿街45号

Applicant address:

Xuanwu Hospital, Capital Medical University, 45 Changchun Street, Xicheng District, Beijing

Study leader's address:

Changchunjie Street

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2024]328号-004

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会-B

Name of the ethic committee:

Ethics Committee of Xuanwu Hospital Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-18 00:00:00

伦理委员会联系人:

张卓然

Contact Name of the ethic committee:

ZHANG ZHUO RAN

伦理委员会联系地址:

北京市西城区长椿街45号

Contact Address of the ethic committee:

Changchunjie Street

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 83199270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xwzhuoranzhang@163.com

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

Changchunjie Street

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital Capital Medical University

Address:

Changchunjie Street

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Optional project

Target disease:

Deep venous thrombosis of lower extremity in patients with severe neurological coma

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

以神经重症昏迷患者为研究对象,使用自动脚踝活动仪完成踝关节被动运动,以期减少下肢深静脉血栓的发生率。  

Objectives of Study:

In order to reduce the incidence of deep venous thrombosis of lower limbs, passive ankle movement was performed by automatic ankle movometer in patients with severe neurological coma.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、年龄>=18岁,性别不限,新入NICU基本无肢体主动运动的患者;
2、5<=GCS<=9分且超声检查排除下肢已经存在DVT的术后已经复苏患者或者2周内无需手术的患者;
3、预期2周内均在NICU持续住院患者;
4、下肢健全,无截肢或者其他原因导致的结构性异常或存在影响关节活动的其他因素;
5、法定代理人自愿同意患者参加本研究并签署知情同意书的患者。

Inclusion criteria

1、age >=18 years old, gender unlimited, new to the NICU basically no active limb movement patients;
2、 5<=GCS<=9 score and ultrasound examination excluded patients who had been resuscitation after surgery or who did not need surgery within 2 weeks;
3、 Patients who are expected to remain hospitalized in NICU within 2 weeks;
4、the lower limbs are sound, no structural abnormalities caused by amputation or other reasons or other factors affecting joint activity;
5、Patients whose legal representatives voluntarily agree to participate in this study and sign informed consent.

排除标准:

1.符合以下各条之一者,不能入组:1、病情严重,血流动力学不稳定的患者;
2、下肢肢体残缺或关节结构性病变影响被动活动者;
3、入院已经明确有严重凝血功能障碍甚至确诊DVT者;
4、基线前1个月内参加其他任何临床试验者;
5、研究者认为存在不合适参加本研究的情况;
6、在入组前1周内以及入组后接受抗凝或者抗板治疗的患者。

Exclusion criteria:

1.Those who meet one of the following conditions are not eligible for inclusion:1、Patients with severe disease and unstable hemodynamics;
2、 lower extremity limb deformity or joint structural disease affect passive activity;
3、Patients admitted to hospital have been clearly diagnosed with severe coagulation dysfunction or even diagnosed with DVT;
4、Participants in any other clinical trial within 1 month before baseline;
5、The researcher believes that it is inappropriate to participate in this study;
6、Patients who received anticoagulation or antiplate therapy within 1 week before and after enrollment.

研究实施时间:

Study execute time:

From 2025-02-14 00:00:00 To 2025-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-14 00:00:00 To 2025-09-30 00:00:00  

干预措施:

Interventions:

组别:

干预1组

样本量:

20

Group:

Intervention group 1

Sample size:

干预措施:

弹力袜(24h穿戴)+脚踝自动活动仪治疗每日2次,干预2周,间隔>=4小时,每次30min

干预措施代码:

Intervention:

Elastic socks (24h wear) + ankle automatic activity meter treatment twice a day, intervention for 2 weeks, interval >=4 hours, 30min each time

Intervention code:

组别:

对照组

样本量:

20

Group:

Control group

Sample size:

干预措施:

24h穿戴弹力袜

干预措施代码:

Intervention:

24h Wear stretch socks

Intervention code:

组别:

干预2组

样本量:

20

Group:

Intervention group 2

Sample size:

干预措施:

干预组2:弹力袜(24h穿戴)+脚踝自动活动仪治疗每日4次,干预2周,间隔>=4小时,每次30min

干预措施代码:

Intervention:

Intervention group 2: elastic socks (24h wear) + ankle automatic activity meter treatment 4 times a day for 2 weeks, intervention interval >=4 hours,

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

首都医科大学宣武医院 

单位级别:

三级甲等 

Institution
hospital:

Xuanwu Hospital Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

下肢静脉血栓形成率

指标类型:

主要指标

Outcome:

Lower extremity venous thrombosis rate

Type:

Primary indicator

测量时间点:

干预开始第1、3、7、14天

测量方法:

干预开始第1、3、7、14天分别由有资质的超声医生,进行下肢血管超声评估血栓发生情况

Measure time point of outcome:

The intervention began on days 1, 3, 7, and 14

Measure method:

On the 1st, 3rd, 7th and 14th day of intervention, the lower extremity blood vessel ultrasound was performed by qualified sonographers to evaluate the occurrence of thrombosis

指标中文名:

2周内形成的血栓静脉分支数

指标类型:

次要指标

Outcome:

Number of thrombotic vein branches formed within 2 weeks

Type:

Secondary indicator

测量时间点:

干预开始第1、3、7、14天

测量方法:

干预开始第1、3、7、14天分别由有资质的超声医生,进行下肢血管超声评估血栓发生情况

Measure time point of outcome:

The intervention began on days 1, 3, 7, and 14

Measure method:

On the 1st, 3rd, 7th and 14th day of intervention, the lower extremity blood vessel ultrasound was performed by qualified sonographers to evaluate the occurrence of thrombosis

指标中文名:

2周内D-Dimer变化率

指标类型:

次要指标

Outcome:

Change rate of D-Dimer within 2 weeks

Type:

Secondary indicator

测量时间点:

干预开始第1、3、7、14天

测量方法:

干预开始第1、3、7、14天留取静脉血标本进行D-Dimer监测

Measure time point of outcome:

The intervention began on days 1, 3, 7, and 14

Measure method:

Venous blood samples were collected at 1, 3, 7 and 14 days after intervention for D-Dimer monitoring

指标中文名:

2周内的肌酸激酶变化率

指标类型:

次要指标

Outcome:

Creatine kinase change rate over 2 weeks

Type:

Secondary indicator

测量时间点:

干预开始第1、3、7、14天

测量方法:

干预开始第1、3、7、14天留取静脉血标本进行肌酸激酶监测

Measure time point of outcome:

The intervention began on days 1, 3, 7, and 14

Measure method:

Venous blood samples were collected at 1, 3, 7 and 14 days after the intervention for creatine kinase monitoring

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表法进行随机分组,信封法随机化分配隐藏,将随机序号保存在密闭不透光的信封内,入一例患者,拆开一个信封,将患者分为干预1组、干预2组及对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method was used for random grouping, and envelope method was used for random allocation and hiding. Random serial numbers were stored in a closed and opaque envelope, a patient was admitted, and an envelope was opened, and the patients were divided into intervention group 1, intervention group 2 and control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签

Blinding:

Open-label study

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

可通过邮件申请从课题负责人处获得,邮箱wangna163_com@126.com.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

They can be obtained from the project manager by email at wangna163_com@126.com.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-02-05 16:09:21